The predictive ability of the CHADS2 and CHA2DS 2-VASc scores for bleeding risk in atrial fibrillation: The MAQI 2 experience

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 294-299

  Barnes, Geoffrey D ^a   Gu, Xiaokui ^a   Haymart, Brian ^a   Kline Rogers, Eva ^a   Almany, Steve ^b   Kozlowski, Jay ^c   Besley, Dennis ^d   Krol, Gregory D ^e   Froehlich, James B ^a   Kaatz, Scott ^f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c Huron Valley Sinai Hospital   (United States)

^d West Michigan Orthopaedics   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f HURLEY MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Atrial Fibrillation; Risk Factors; Stroke; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIA SCORE; BLEEDING; CHA2DS2 VASC SCORE; CHADS2 SCORE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HEMORR2 HAGES SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; RISK FACTOR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; WARFARIN;

EID: 84905120663     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.034     Document Type: Article

References (40)

1. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
2. G. Palareti, and B. Cosmi Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients Thromb Haemost. 102 2009 268 278
3. J.J. You, D.E. Singer, P.A. Howard, D.A. Lane, M.H. Eckman, and M.C. Fang et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
4. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
5. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
6. B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, and M.W. Rich et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
7. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
8. M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, and N. Udaltsova et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 2011 395 401
9. S. Apostolakis, D.A. Lane, Y. Guo, H. Buller, and G.Y. Lip Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study J Am Coll Cardiol 60 2012 861 867
10. S. Apostolakis, D.A. Lane, Y. Guo, H. Buller, and G.Y. Lip Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients J Am Coll Cardiol 61 2013 386 387
11. G.Y. Lip, H.J. Lin, H.C. Hsu, T.C. Su, M.F. Chen, and Y.T. Lee et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study Int J Cardiol 57 2013 173 180
12. V. Roldán, F. Marín, H. Fernández, S. Manzano-Fernandez, P. Gallego, and M. Valdés et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy Chest 143 2013 179 184
13. J. Donzé, N. Rodondi, G. Waeber, P. Monney, J. Cornuz, and D. Aujesky Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study Am J Med 125 2012 1095 1102
14. J.A. Cairns, S. Connolly, S. McMurtry, M. Stephenson, M. Talajic, and C.A.F.G. Committee Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter Can J Cardiol 27 2011 74 90
15. G.Y. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, and E. Knight et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis Europace 13 2011 723 746
16. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Europace 12 2010 1360 1420
17. D.C. Suh, J.C. Choi, J. Schein, S. Kim, and W.W. Nelson Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients Curr Med Res Opin. 29 2013 761 771
18. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, H. Yang, J. Ansell, and M.C. Bahit et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial Lancet 380 2012 1749 1758
19. J. Oldgren, M. Alings, H. Darius, H.C. Diener, J. Eikelboom, and M.D. Ezekowitz et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann Intern Med 155 2011 660 667 [W204]
20. G.D. Barnes, S. Kaatz, V. Golgotiu, X. Gu, A. Leidal, and A. Kobeissy et al. Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) J Thromb Thrombolysis 35 2013 10 14
21. G.D. Barnes, S. Kaatz, J. Winfield, X. Gu, B. Haymart, and E. Kline-Rogers et al. Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) J Thromb Thrombolysis 37 2014 171 176
22. G.Y. Lip, A. Banerjee, I. Lagrenade, D.A. Lane, S. Taillandier, and L. Fauchier Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project Circ Arrhythm Electrophysiol 5 2012 941 948
23. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
24. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
25. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 [discussion 207-12]
26. S. Apostolakis, D.A. Lane, H. Buller, and G.Y. Lip Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial Thromb Haemost 110 2013
27. V. Roldan, F. Marin, S. Manzano-Fernandez, P. Gallego, J.A. Vilchez, and M. Valdes et al. The HAS-BLED score has better prediction accuracy for major bleeding than the CHADS or CHADS-VASc scores In anticoagulated patients with atrial fibrillation J Am Coll Cardiol 62 2013 2199 2204
28. S. Rietbrock, E. Heeley, J. Plumb, and T. van Staa Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme Am Heart J 156 2008 57 64
29. J.P. Piccini, S.R. Stevens, Y. Chang, D.E. Singer, Y. Lokhnygina, and A.S. Go et al. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts Circulation 127 2013 224 232
30. J.B. Olesen, G.Y. Lip, M.L. Hansen, P.R. Hansen, J.S. Tolstrup, and J. Lindhardsen et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
31. J.B. Olesen, G.Y. Lip, P.R. Hansen, J. Lindhardsen, O. Ahlehoff, and C. Andersson et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort J Thromb Haemost 9 2011 1460 1467
32. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
33. J.B. Olesen, G.Y. Lip, J. Lindhardsen, D.A. Lane, O. Ahlehoff, and M.L. Hansen et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study Thromb Haemost 106 2011 739 749
34. T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen, and R. Linder et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb Haemost 107 2012 1053 1065
35. G. Gussoni, G. Di Pasquale, G. Vescovo, M. Gulizia, G. Mathieu, and M. Scherillo et al. Decision making for oral anticoagulants in atrial fibrillation: The ATA-AF study Eur J Intern Med 24 2013 324 332
36. M.B. Rosenman, L. Baker, Y. Jing, D. Makenbaeva, B. Meissner, and T.A. Simon et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records Curr Med Res Opin 28 2012 1407 1414
37. P. Gallego, V. Roldan, F. Marin, M. Romera, M. Valdes, and V. Vicente et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198
38. E.W. Steyerberg, and M.J. Pencina Reclassification calculations for persons with incomplete follow-up Ann Intern Med 152 2010 195 196 [author reply 6-7]
39. V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
40. K.L. Furie, L.B. Goldstein, G.W. Albers, P. Khatri, R. Neyens, and M.P. Turakhia et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association Stroke 43 2012 3442 3453